Pharma’s Data Deluge Finds a Home in the Cloud

Drugmakers are harnessing cloud platforms to accelerate genomics research and modernize data-driven drug discovery

7 Jan 2026

Cloud computing is becoming a central part of how US pharmaceutical companies conduct genomics-led drug research, as rising data volumes push the industry beyond traditional laboratory and IT models.

Over the past year, large drugmakers have increased spending on cloud platforms to store and analyse biological data generated by genomics and related “omics” technologies. Executives and analysts say this marks a shift in how medicines are discovered and developed, rather than a routine upgrade of computing systems.

AstraZeneca illustrates the trend. The company has said it manages genomic datasets at petabyte scale using cloud-based storage and analytics. These platforms allow large datasets to be processed more quickly than conventional in-house systems, reducing the time needed to test hypotheses and assess early-stage drug candidates. Faster feedback enables researchers to discard weak options sooner and focus resources on more promising targets.

Adoption across the sector is uneven, but momentum is building. Most large pharmaceutical groups are pursuing hybrid models that combine public cloud services with internal data centres. Amazon Web Services and Google Cloud have become important partners, offering infrastructure designed to meet security and compliance requirements for sensitive health and research data.

The appeal lies partly in flexibility. Cloud platforms allow computing power to scale up as needed and support collaboration across global research teams, universities and contract research organisations. Such partnerships are now a core feature of drug development, and shared digital infrastructure can reduce duplication of work and shorten development timelines.

Analysts say the move is driven as much by necessity as by ambition. Advances in sequencing and data analysis have produced data volumes that are difficult and costly to manage using on-site systems alone. Hybrid cloud models help relieve capacity constraints while maintaining a degree of control over critical datasets.

Obstacles remain. Pharmaceutical data is heavily regulated, requiring strong controls over privacy, data integrity and auditability. Managing hybrid environments can add operational complexity, and cybersecurity risks demand constant oversight.

Despite these challenges, industry confidence is growing. As cloud tools mature and regulatory guidance becomes clearer, data-intensive research is expected to become standard practice. Companies that build effective cloud-enabled data strategies are likely to be better placed as genomic medicine moves into its next phase.